[go: up one dir, main page]

PE20150222A1 - Anticuerpos multiespecificos - Google Patents

Anticuerpos multiespecificos

Info

Publication number
PE20150222A1
PE20150222A1 PE2014002488A PE2014002488A PE20150222A1 PE 20150222 A1 PE20150222 A1 PE 20150222A1 PE 2014002488 A PE2014002488 A PE 2014002488A PE 2014002488 A PE2014002488 A PE 2014002488A PE 20150222 A1 PE20150222 A1 PE 20150222A1
Authority
PE
Peru
Prior art keywords
growth
specific antibodies
sequence
epiderman
endothellum
Prior art date
Application number
PE2014002488A
Other languages
English (en)
Inventor
Jenny M Bostrom
Germaine Fuh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41399375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20150222A1 publication Critical patent/PE20150222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ANTICUERPO AISLADO QUE COMPRENDE UNA SECUENCIA DE REGION HIPERVARIABLE (HVR) L1 QUE COMPRENDE LA SECUENCIA NIAKTISGY ( SEQ ID NO: 1), EN DONDE DICHO ANTICUERPO ENLAZA ESPECIFICAMENTE UN RECEPTOR DE CRECIMIENTO EPIDERMICO HUMANO 2 (HER2) Y UN FACTOR DE CRECIMIENTO ENDOTELIO VASCULAR (VEGF).
PE2014002488A 2008-09-03 2009-09-01 Anticuerpos multiespecificos PE20150222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19085608P 2008-09-03 2008-09-03

Publications (1)

Publication Number Publication Date
PE20150222A1 true PE20150222A1 (es) 2015-03-02

Family

ID=41399375

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011000442A PE20110593A1 (es) 2008-09-03 2009-09-01 Anticuerpos multiespecificos
PE2014002488A PE20150222A1 (es) 2008-09-03 2009-09-01 Anticuerpos multiespecificos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011000442A PE20110593A1 (es) 2008-09-03 2009-09-01 Anticuerpos multiespecificos

Country Status (19)

Country Link
US (3) US8193321B2 (es)
EP (1) EP2324061B1 (es)
JP (1) JP5796831B2 (es)
KR (1) KR101705911B1 (es)
CN (1) CN102143977B (es)
AR (1) AR073538A1 (es)
AU (1) AU2009288167B2 (es)
BR (1) BRPI0918648A2 (es)
CA (1) CA2734905A1 (es)
ES (1) ES2628108T3 (es)
IL (1) IL211349A0 (es)
MX (1) MX353984B (es)
PE (2) PE20110593A1 (es)
PH (1) PH12013502230A1 (es)
RU (1) RU2547596C2 (es)
SG (1) SG193851A1 (es)
TW (1) TWI487712B (es)
WO (1) WO2010027981A1 (es)
ZA (1) ZA201101970B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
AU2009288167B2 (en) 2008-09-03 2015-10-22 Genentech, Inc. Multispecific antibodies
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9714294B2 (en) 2010-05-27 2017-07-25 Genmab A/S Monoclonal antibodies against HER2 epitope
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
WO2012098113A1 (en) * 2011-01-17 2012-07-26 Novo Nordisk A/S Il-21 ligands
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
KR101453516B1 (ko) 2011-09-20 2014-10-24 가톨릭대학교 산학협력단 항-ｖｅｇｆ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US20160000787A1 (en) * 2013-02-26 2016-01-07 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
CN113278076A (zh) * 2013-11-11 2021-08-20 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
JP2015097496A (ja) * 2013-11-19 2015-05-28 国立大学法人 東京大学 Ｒｏｂｏ１に対する親和性を向上させた抗体及び高親和性抗体の分子設計方法
WO2015119841A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Role of il-23 and pd-1 in autoreactive immune response
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016042684A1 (ja) * 2014-09-16 2016-03-24 国立大学法人東京海洋大学 濃縮された生着能をもつ未分化生殖細胞を用いた生殖細胞系列への分化誘導方法
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
WO2017034770A1 (en) 2015-08-26 2017-03-02 Bison Therapeutics Inc. Multispecific antibody platform and related methods
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
GB201521447D0 (en) * 2015-12-04 2016-01-20 Ucb Biopharma Sprl De novo antibody design
WO2017132457A1 (en) * 2016-01-28 2017-08-03 Janssen Biotech, Inc. BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE
EP3634999A1 (en) * 2017-06-07 2020-04-15 Philogen S.p.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN107602702A (zh) 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
TWI799824B (zh) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Ｄｌｌ３靶向之多特異性抗原結合分子及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0710719B1 (en) 1990-01-12 2007-03-14 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
KR100254759B1 (ko) 1992-01-23 2000-05-01 플레믹 크리스티안 단량체 및 이량체 항체-단편 융합 단백질
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CN1451043A (zh) 2000-06-29 2003-10-22 艾博特公司 双特异性抗体及其制备方法和用途
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
JP2002355074A (ja) * 2001-01-24 2002-12-10 Univ Tsukuba 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2003018749A2 (en) 2001-08-22 2003-03-06 Shengfeng Li Compositions and methods for generating antigen-binding units
AU2003239966B9 (en) * 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
EP2311875A1 (en) 2003-05-30 2011-04-20 Genentech, Inc. Treatment with anti-VEGF antibodies
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
JP2008509666A (ja) 2004-08-11 2008-04-03 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合ドメイン融合タンパク質
AU2006332212B8 (en) * 2006-01-04 2013-05-30 Institut National De La Sante Et De La Recherche Medicale Combination therapy using anti-EGFR and anti-HER2 antibodies
GEP20135917B (en) * 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
DE112008003232T5 (de) 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-Bindungskonstrukte
AU2009288167B2 (en) 2008-09-03 2015-10-22 Genentech, Inc. Multispecific antibodies

Also Published As

Publication number Publication date
AR073538A1 (es) 2010-11-17
US9017686B2 (en) 2015-04-28
AU2009288167A1 (en) 2010-03-11
JP2012501648A (ja) 2012-01-26
PE20110593A1 (es) 2011-09-10
CN102143977A (zh) 2011-08-03
AU2009288167B2 (en) 2015-10-22
CN102143977B (zh) 2014-08-06
JP5796831B2 (ja) 2015-10-21
US20150315290A1 (en) 2015-11-05
US9522960B2 (en) 2016-12-20
US8193321B2 (en) 2012-06-05
RU2547596C2 (ru) 2015-04-10
PH12013502230A1 (en) 2016-01-25
MX2011002389A (es) 2011-05-23
WO2010027981A1 (en) 2010-03-11
EP2324061B1 (en) 2017-04-12
KR101705911B1 (ko) 2017-02-10
US20100322946A1 (en) 2010-12-23
IL211349A0 (en) 2011-05-31
EP2324061A1 (en) 2011-05-25
US20110142852A1 (en) 2011-06-16
RU2011112324A (ru) 2012-10-10
CA2734905A1 (en) 2010-03-11
ZA201101970B (en) 2012-05-30
KR20110081812A (ko) 2011-07-14
ES2628108T3 (es) 2017-08-01
TW201011047A (en) 2010-03-16
MX353984B (es) 2017-11-27
BRPI0918648A2 (pt) 2019-09-03
TWI487712B (zh) 2015-06-11
SG193851A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
PE20150222A1 (es) Anticuerpos multiespecificos
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
UA101487C2 (en) Humanized b-ly1 antibody formulation
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
NZ621938A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ616382A (en) Antibodies specific to cadherin-17
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
GT200900043A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
UA111818C2 (uk) Антитіло проти csf-1r
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
EA201100868A1 (ru) Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин
NZ602294A (en) Monoclonal antibodies against c-met
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010145792A8 (en) Bispecific antigen binding proteins

Legal Events

Date Code Title Description
FD Application declared void or lapsed